Multicenter quality control of hepatitis C virus protease inhibitor resistance genotyping.

S Vallet, S Larrat, S Laperche, H Le Guillou-Guillemette, F Legrand-Abravanel, F Bouchardeau, A Pivert, C Henquell, A Mirand, E Andre-Garnier, V Giordanengo, G Lagathu, V Thibault, C Scholtes, E Schvoerer, C Gaudy-Graffin, S Maylin, P Trimoulet, E Brochot, S Hantz, J Gozlan, AM Roque-Afonso, P Soussan, JC Plantier, C Charpentier, Stephane CHEVALIEZ, P Colson, V Mackiewicz, L Aguilera, S Rosec, S Gouriou, N Magnat, F Lunel-Fabiani, J Izopet, P Morand, C Payan, Jean-Michel PAWLOTSKY,

J Clin Microbiol. 01/05/2013;51(5) : 1428-1433 10.1128/JCM.03032-12 20/02/2013

Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.

MS Sulkowski, M Bourliere, JP Bronowicki, T Asselah, Jean-Michel PAWLOTSKY, SD Shafran, S Pol, S Mauss, D Larrey, Y Datsenko, JO Stern, G Kukolj, J Scherer, G Nehmiz, GG Steinmann, WO Bocher,

Hepatology. 01/05/2013;57(6) : 2155-2163 10.1002/hep.26386.

Regulation of hepatitis C virus replication by nuclear translocation of nonstructural 5A protein and transcriptional activation of host genes.

MA Maqbool, MR Imache, MR Higgs, S Carmouse, Jean-Michel PAWLOTSKY, H Lerat,

J Virol. 01/05/2013;87(10) : 5523-5539 10.1128/JVI.00585-12 06/03/2013

The Cobas AmpliPrep/Cobas TaqMan HCV test, version 2.0, real-time PCR assay accurately quantifies hepatitis C virus genotype 4 RNA.

Stephane CHEVALIEZ, Magali BOUVIER-ALIAS, Christophe RODRIGUEZ, Alexandre SOULIER, JD Poveda, Jean-Michel PAWLOTSKY,

J Clin Microbiol. 01/04/2013;51(4) : 1078-1082 10.1128/JCM.02004-12. 16/01/2013

Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely.

Stephane CHEVALIEZ, Christophe HEZODE, S Bahrami, M Grare, Jean-Michel PAWLOTSKY,

J Hepatol. 01/04/2013;58(4) : 676-683 10.1016/j.jhep.2012.11.039. 03/12/2012

Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection.

SJ Polyak, P Ferenci, Jean-Michel PAWLOTSKY,

Hepatology 01/03/2013;57(3) : 1262-1271 10.1002/hep.26179.

Treatment of hepatitis C: how will we use viral kinetics, response-guided therapy?

Jean-Michel PAWLOTSKY,

Curr Gastroenterol Rep. 01/02/2013;15(2) : 309 10.1007/s11894-012-0309-x.

Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I.

Julien CALDERARO, P Labrune, G Morcrette, S Rebouissou, D Franco, S Prevot, A Quaglia, P Bedossa, L Libbrecht, L Terracciano, GP Smit, P Bioulac-Sage, J Zucman-Rossi,

J Hepatol. 01/02/2013;58(2) : 350-357 10.1016/j.jhep.2012.09.030 06/10/2012

How to optimize HCV therapy in genotype 1 patients with cirrhosis.

M Bourliere, A Wendt, H Fontaine, Christophe HEZODE, S Pol, JP Bronowicki,

Liver Int 01/02/2013;33 Suppl 1 : 46-55 10.1111/liv.12067.

Hepatitis C virus: standard-of-care treatment.

Jean-Michel PAWLOTSKY,

Adv Pharmacol 01/01/2013;67 : 169-215 10.1016/B978-0-12-405880-4.00005-6.